FindMyRecallSubscribe
Class I: serious health riskTerminated

Bethel Nutritional Consulting Quick Thin Recall

Quick Thin (citrus aurantium extract, sweet potato fiber, cyamopsis gum powder, alfalfa…

Bethel Nutritional Consulting, Inc · New York, NY

Risk level
Class I
Reported by FDA
Dec 25, 2013
Recall ID
D-371-2014
Check your lot numberHow we source this data

Summary

Bethel Nutritional Consulting recalled Quick Thin starting Aug 5, 2013. The FDA classified it as Class I (serious health risk) and published enforcement report D-371-2014 on Dec 25, 2013. Reason: Marketed Without An Approved NDA/ANDA: FDA analysis detected the presence of sibutramine, N-Desmethylsibutramine and phenolphthalein. Sibutramine and phenolphthalein were previously available drug products but were removed from the U.S. market making these products unapproved new drugs. Status: Terminated.

Why it was recalled

Marketed Without An Approved NDA/ANDA: FDA analysis detected the presence of sibutramine, N-Desmethylsibutramine and phenolphthalein. Sibutramine and phenolphthalein were previously available drug products but were removed from the U.S. market making these products unapproved new drugs.

Product description

Quick Thin (citrus aurantium extract, sweet potato fiber, cyamopsis gum powder, alfalfa, mulberry leaf, guarana, spirulina) capsules, 400 mg, 30-count bottle, Distributed by: Bethel, Inc., Tel: (212) 568-5330.

Lot numbers, UPCs & expiration codes

Lot 10032011, Exp 10/14

Where it was sold

Nationwide, Puerto Rico, and internet sales

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-371-2014
Classification
Class I
Status
Terminated
Recall initiated
Aug 5, 2013
FDA report date
Dec 25, 2013
Quantity
9,121 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Bethel Nutritional Consulting, Inc

Original FDA data

Every field from FDA enforcement report D-371-2014, exactly as published.

Show all FDA fields
City
New York
State
NY
Status
Terminated
Country
United States
Event ID
65894
Address
599 W 190th St Ste 1
Code information
Lot 10032011, Exp 10/14
Postal code
10040-3577
Report date
Dec 25, 2013
Product type
Drugs
Recall number
D-371-2014
Classification
Class I
Recalling firm
Bethel Nutritional Consulting, Inc
Product quantity
9,121 bottles
Termination date
May 30, 2018
Reason for recall
Marketed Without An Approved NDA/ANDA: FDA analysis detected the presence of sibutramine, N-Desmethylsibutramine and phenolphthalein. Sibutramine and phenolphthalein were previously available drug products but were removed from the U.S. market making these products unapproved new drugs.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Quick Thin (citrus aurantium extract, sweet potato fiber, cyamopsis gum powder, alfalfa, mulberry leaf, guarana, spirulina) capsules, 400 mg, 30-count bottle, Distributed by: Bethel, Inc., Tel: (212) 568-5330.
Distribution pattern
Nationwide, Puerto Rico, and internet sales
Recall initiation date
Aug 5, 2013
Initial firm notification
Press Release
Center classification date
Dec 18, 2013

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-371-2014, published Dec 25, 2013. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls